The Deeley Research Centre (DRC) is a key site for BC Cancer’s Immunotherapy Program. Researchers at the DRC are studying how the immune system responds to cancer and how best to enhance this response for therapeutic purposes. The Immunotherapy Program is translating discoveries from the DRC and our many collaborators into innovative clinical trials, offering promising new treatment options for patients with cancer.
Thanks to generous support of the Conconi family and thousands of other donors to the BC Cancer Foundation, as well as grants from the Canada Foundation for Innovation and the BC Knowledge Development Fund, the DRC is home to the Conconi Family Immunotherapy Lab (CFIL). CFIL is an advanced cell manufacturing facility that produces natural and genetically engineered T cell products for clinical trials in BC and other sites in Canada.
The DRC is also home to the Molecular and Cellular Immunology Core, and supports BC Cancer’s Biobanking and Biospecimen Research Services.
